期刊文献+

VEGFR-2酪氨酸激酶抑制剂3-取代吲哚-2-酮的合成及抑制活性 被引量:1

Synthesis and inhibition activity of 3-substituted indolin-2-ones as inhibitors of VEGFR-2 tyrosine kinase
下载PDF
导出
摘要 目的:合成一系列结构新颖的3-取代吲哚-2-酮类化合物,并测试其对血管内皮生长因子受体-2(VEGFR-2)的抑制活性。方法:以2-(羟甲基)-5-氰基-1H-吲哚为起始原料,经水解、氧化、缩合和胺化反应得到目标产物(6-14);以舒尼替尼为阳性对照,用MTT法测试目标产物对VEGFR-2高表达的人乳腺上皮细胞(HMEC)的抑制活性。结果:合成9个未见报道的目标产物,其结构均经1H NMS,ESI-MS确证;样品浓度为10μmol/L时,化合物14对VEGFR-2的抑制率为68.56%,舒尼替尼为62.53%。结论:化合物14对VEGFR-2的抑制活性优于阳性对照舒尼替尼。 Objective: To synthesize a series of novel 3 substituted indolin-2-ones and to determine their inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR 2). Methods: 2-( hydroxymethyl)-5- carbonitrile-1 H-indole were used as the starting material, target compounds were synthesized via hydrolyzation, oxidation, condensation and amination reaction. The activities of the target compounds were evaluated with HMEC (on kind of cell lines high expressing VEGFR-2 tyro.sine kinase) in vitro through measuring cell viability by MTT method and sunitinib was a positive control. Results: There are no reports for the synthesis of target compounds and their structures were identified by ^1 H NMS, MS. At the concentration of 10 mol/L, compound 14 showed 68.56% inhibitory activity against VEGFR 2, while the inhibition ratio of sunitinib was 62.53%. Conclusion: Compound 14 shows higher inhibition ratio against VEGFR 2 than that of sunitinib.
出处 《河南大学学报(医学版)》 CAS 2009年第2期110-114,共5页 Journal of Henan University:Medical Science
关键词 蛋白酪氨酸激酶 血管内皮生长因子受体-2 3-取代吲哚-2-酮 Protein tyrosine kinase Vascular endothelial growth factor receptor-2 3 substituted indolin-2 ones
  • 相关文献

参考文献10

  • 1Li S,Ngoc T,Congxin N L,et al.Design,synthesis,andevaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors ofVEGF,FGF and PDGF receptor tyrosine kinases[].Journal of Medicinal Chemistry.1999
  • 2Jack A B,Natasja B,Allan W,et al.Kinase domainmutations in cancer:implications for small molecule drugdesign strategies[].Journal of Medicinal Chemistry.2009
  • 3Sandrine F,George D,William S,et al.Molecular basisfor sunitinib efficacy and future clinical development[].Nature Reviews Drug Discovery.2007
  • 4Robert R J.Sunitinib:a VEGF and PDGF receptorprotein kinase and angiogenesis inhibitor[].Biochemical and Biophysical Research Communications.2007
  • 5Folkman J.Tumor angiogenesis: therapeutic implications[].New England Journal of Homeopathy.1971
  • 6J Folkman.Angiogenesis: an organizing principle for drug discovery?[].Nature Reviews Drug Discovery.2007
  • 7Li S,Ngoc T,Flora T,et al.Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases[].Journal of Medicinal Chemistry.1998
  • 8Sun L,Tran N,Liang C,et al.Identification of Substituted 3-[ (4, 5, 6, 7-Tetrahydro-1H- indol-2-yl) methylene]- 1, 3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 ( Flk-1/ KDR), FGF-R1, and PDGF-R Tyrosine Kinases[].Journal of Medicinal Chemistry.2000
  • 9Sun Li,Liang Chris,Shirazian Sheri,et al.Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylami-noethyl)amide,a novel tyrosine kinase inhibitor targetingvascular endothelial and platelet-derived growth factor re-ceptor tyrosine[].Journal of Medicinal Chemistry.2003
  • 10Satoshi Komoriya a> Naoaki Kanaya,Takayasu Nagahara,Asako Yokoyama,Kazue Inamura,Yukio Yokoyama,Shin-ichi Katakura and Tsuyoshi Hara.Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites[].Bioorganic and Medicinal Chemistry.2004

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部